JP2013529078A5 - - Google Patents

Download PDF

Info

Publication number
JP2013529078A5
JP2013529078A5 JP2013510354A JP2013510354A JP2013529078A5 JP 2013529078 A5 JP2013529078 A5 JP 2013529078A5 JP 2013510354 A JP2013510354 A JP 2013510354A JP 2013510354 A JP2013510354 A JP 2013510354A JP 2013529078 A5 JP2013529078 A5 JP 2013529078A5
Authority
JP
Japan
Prior art keywords
seq
borrelia
composition
amino acid
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013510354A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013529078A (ja
JP6227407B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/036533 external-priority patent/WO2011143623A1/en
Publication of JP2013529078A publication Critical patent/JP2013529078A/ja
Publication of JP2013529078A5 publication Critical patent/JP2013529078A5/ja
Application granted granted Critical
Publication of JP6227407B2 publication Critical patent/JP6227407B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013510354A 2010-05-14 2011-05-13 Ｏｓｐａキメラおよびそのワクチンでの使用法 Expired - Fee Related JP6227407B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33490110P 2010-05-14 2010-05-14
US61/334,901 2010-05-14
PCT/US2011/036533 WO2011143623A1 (en) 2010-05-14 2011-05-13 Ospa chimeras and use thereof in vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016126608A Division JP2016168057A (ja) 2010-05-14 2016-06-27 Ｏｓｐａキメラおよびそのワクチンでの使用法

Publications (3)

Publication Number Publication Date
JP2013529078A JP2013529078A (ja) 2013-07-18
JP2013529078A5 true JP2013529078A5 (cg-RX-API-DMAC7.html) 2014-06-26
JP6227407B2 JP6227407B2 (ja) 2017-11-08

Family

ID=44121257

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2013510352A Expired - Fee Related JP6030052B2 (ja) 2010-05-14 2011-05-13 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2013510354A Expired - Fee Related JP6227407B2 (ja) 2010-05-14 2011-05-13 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2016126608A Withdrawn JP2016168057A (ja) 2010-05-14 2016-06-27 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2016126631A Pending JP2016171816A (ja) 2010-05-14 2016-06-27 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2018129896A Withdrawn JP2018150386A (ja) 2010-05-14 2018-07-09 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2020135857A Expired - Fee Related JP6965417B2 (ja) 2010-05-14 2020-08-11 Ｏｓｐａキメラおよびそのワクチンでの使用法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013510352A Expired - Fee Related JP6030052B2 (ja) 2010-05-14 2011-05-13 Ｏｓｐａキメラおよびそのワクチンでの使用法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2016126608A Withdrawn JP2016168057A (ja) 2010-05-14 2016-06-27 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2016126631A Pending JP2016171816A (ja) 2010-05-14 2016-06-27 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2018129896A Withdrawn JP2018150386A (ja) 2010-05-14 2018-07-09 Ｏｓｐａキメラおよびそのワクチンでの使用法
JP2020135857A Expired - Fee Related JP6965417B2 (ja) 2010-05-14 2020-08-11 Ｏｓｐａキメラおよびそのワクチンでの使用法

Country Status (13)

Country Link
US (6) US8623376B2 (cg-RX-API-DMAC7.html)
EP (4) EP2569008B1 (cg-RX-API-DMAC7.html)
JP (6) JP6030052B2 (cg-RX-API-DMAC7.html)
KR (7) KR102222869B1 (cg-RX-API-DMAC7.html)
CN (3) CN107641151B (cg-RX-API-DMAC7.html)
AU (2) AU2011252844B2 (cg-RX-API-DMAC7.html)
BR (2) BR112012027315B1 (cg-RX-API-DMAC7.html)
CA (2) CA2799181C (cg-RX-API-DMAC7.html)
MX (3) MX375965B (cg-RX-API-DMAC7.html)
PL (2) PL2569009T3 (cg-RX-API-DMAC7.html)
RU (2) RU2636455C2 (cg-RX-API-DMAC7.html)
SI (2) SI2569008T1 (cg-RX-API-DMAC7.html)
WO (2) WO2011143617A1 (cg-RX-API-DMAC7.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2569008B1 (en) * 2010-05-14 2019-12-25 Baxalta Incorporated Ospa chimeras and use thereof in vaccines
US20120123924A1 (en) 2010-10-20 2012-05-17 Mark Rose Virtual currency configuration apparatuses, methods and systems
US10438176B2 (en) 2011-07-17 2019-10-08 Visa International Service Association Multiple merchant payment processor platform apparatuses, methods and systems
US10318941B2 (en) 2011-12-13 2019-06-11 Visa International Service Association Payment platform interface widget generation apparatuses, methods and systems
US10096022B2 (en) * 2011-12-13 2018-10-09 Visa International Service Association Dynamic widget generator apparatuses, methods and systems
US8986704B2 (en) * 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
CN104640563A (zh) * 2012-07-27 2015-05-20 巴克斯特国际公司 包含嵌合的ospa分子的组合物及其使用方法
PL223175B1 (pl) 2012-10-22 2016-10-31 Inst Chemii Bioorganicznej Polskiej Akademii Nauk Szczepionka przeciw boreliozie, konstrukt genetyczny, rekombinowane białko, sposób otrzymywania konstruktu genetycznego, sposób otrzymywania szczepionki, sposób otrzymywania rekombinowanych białek, zastosowanie rekombinowanych białek do wytwarzania szczepionki przeciwko boreliozie
MX371272B (es) * 2013-03-15 2020-01-22 Univ California El péptido mots3 derivado de mitocondrias regula el metabolismo y la supervivencia celular.
WO2015041710A1 (en) * 2013-09-23 2015-03-26 Ventria Bioscience, Inc. Ospa fusion protein for vaccination against lyme disease
BR112016015678B1 (pt) * 2014-01-09 2024-02-06 Valneva Austria Gmbh Polipeptídeo compreendendo um fragmento de ospa de c-terminal híbrido, seu processo de produção, seu uso, ácido nucleico, vetor, célula hospedeira, composição farmacêutica
CZ2014320A3 (cs) * 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
CA2958018A1 (en) 2014-08-11 2016-02-18 University Of Massachusetts Anti-ospa antibodies and methods of use
US11216468B2 (en) 2015-02-08 2022-01-04 Visa International Service Association Converged merchant processing apparatuses, methods and systems
US10735952B2 (en) * 2015-08-14 2020-08-04 Telefonaktiebolaget Lm Ericsson (Publ) Node and method for managing a packet data network connection
KR20210117359A (ko) * 2016-11-07 2021-09-28 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 라임병에 사용하기 위한 dna 항체 작제물
WO2018189372A1 (en) * 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto
CN112584858A (zh) * 2018-04-03 2021-03-30 赛诺菲 抗原性ospa多肽
WO2019195291A1 (en) 2018-04-03 2019-10-10 Sanofi Antigenic respiratory syncytial virus polypeptides
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
EP3773708A2 (en) 2018-04-03 2021-02-17 Sanofi Antigenic epstein barr virus polypeptides
CN110483624B (zh) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 伽氏疏螺旋体OspA蛋白C端肽段及其应用
CN111196842A (zh) * 2020-01-09 2020-05-26 济南大学 一种外膜转运通道蛋白的非跨膜结构域的表达纯化方法
CA3174666A1 (en) 2020-04-09 2021-10-14 Robert Schlegl Improved methods of producing a lipidated protein
BR112022020438A2 (pt) * 2020-04-09 2022-11-29 Valneva Austria Gmbh Composições compreendendo três proteínas de fusão ospa para uso médico
US12228578B2 (en) 2020-12-17 2025-02-18 Idexx Laboratories, Inc. Rocky mountain spotted fever detection and treatment
WO2022261050A1 (en) * 2021-06-07 2022-12-15 The University Of Massachusetts Apparatus and method for continuous production of rna
CA3244889A1 (en) 2022-03-08 2023-09-14 Equashield Medical Ltd FLUID TRANSFER STATION IN A ROBOTIC PHARMACEUTICAL PREPARATION SYSTEM
WO2025015042A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen
WO2025015077A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DK166762B1 (da) 1986-01-14 1993-07-12 Nederlanden Staat Fremgangsmaade til fremstilling af immunogenkomplekser og farmaceutisk sammensaetning indeholdende saadanne komplekser
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4830885A (en) 1987-06-08 1989-05-16 Allied-Signal Inc. Chlorine-resistant semipermeable membranes
US6143872A (en) 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US5777095A (en) 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US7094391B1 (en) 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SG122738A1 (en) * 1990-06-15 2006-06-29 Univ Yale Compositions and methods for the prevention and diagnosis of lyme disease
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ATE168132T1 (de) 1991-02-15 1998-07-15 Uab Research Foundation Strukturgen von pneumokokken-protein
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
DK0598816T3 (da) 1991-08-15 1999-11-22 Deutsches Krebsforsch Osp A-proteiner fra Borrelia Burgdorferi-undergrupper, hvilke proteiner koder for gener og vacciner
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
ES2219657T3 (es) 1993-11-01 2004-12-01 Brookhaven Science Associates Proteinas quimericas que comprenden polipeptidos de borrelia: usos para las mismas.
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
ATE225668T1 (de) 1996-02-12 2002-10-15 Cobra Therapeutics Ltd Neue methode zur impfung sowie impfstoffe dafür, die eine epitopkodierende nukleinsäure und ein epitopenthaltende peptid beinhalten
US6368603B1 (en) * 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
US6660274B2 (en) * 1997-06-30 2003-12-09 The Administrators Of The Tulane Educational Fund Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
GB9726555D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
GB9811219D0 (en) 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
AU2001281145A1 (en) * 2000-08-18 2002-03-04 Brookhaven Sciences Associates, Llc Recombinant constructs of borrelia burgdorferi
PT1311540E (pt) 2000-08-18 2008-03-20 Univ New York State Res Found Ospa de borrelia burgdorferi modificada
EP1939294A1 (en) * 2000-08-18 2008-07-02 Research Foundation Of State University Of New York Recombinant constructs of borrelia burgdorferi
RU2385323C2 (ru) 2003-04-02 2010-03-27 ДЗЕ ГАВЕРМЕНТ ОФ ДЗЕ ЮНАЙТЕД СТЕЙТС ОФ АМЕРИКА Эз репрезентед бай ДЗЕ СЕКРЕТЭРИ, ДЕПАРТМЕНТ ОФ ХЕЛТ ЭНД ХЬЮМЭН СЕРВИСИЗ Холестеринсодержащие соединения и их применение в качестве иммуногенов против borrelia burgdorferi
KR20060019515A (ko) * 2003-04-16 2006-03-03 와이어쓰 홀딩스 코포레이션 수막구균 질환의 예방 및 치료용 신규 면역원성 조성물
DE602005020913D1 (de) * 2004-03-24 2010-06-10 Merck Sharp & Dohme Optimierte expression von hpv-52-l1 in hefe
EP1768688A4 (en) 2004-07-02 2009-09-30 Raymond J Dattwyler ORAL BORRELIOSE VACCINE
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
EP1957520A4 (en) 2005-11-29 2009-05-27 Univ Virginia Commonwealth POLYVALENTIC CHIMERIC OSPC VACCINOGEN AND DIAGNOSTIC ANTIGEN
RU2008126239A (ru) * 2005-11-29 2010-01-10 Вирджиния Коммонвелт Юниверсити (Us) Поливалентный химерный вакциноген и диагностический антиген ospc
CA2661224A1 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
ATE496935T1 (de) 2007-02-22 2011-02-15 Baxter Int Verfahren zur aufreinigung hydrophober proteine
HRP20151122T1 (hr) * 2007-06-26 2015-11-20 Glaxosmithkline Biologicals S.A. Cjepivo koje sadrži konjugate polisaharida iz kapsule bakterije streptococcus pneumoniae
WO2009099716A1 (en) * 2008-01-11 2009-08-13 Vgx Pharmaceuticals, Inc. Novel vaccines against multiple subtypes of dengue virus
US20110105355A1 (en) 2008-04-22 2011-05-05 Research Foundation Of State University Of New York Borrelia burgdorferi cell envelope protein array
WO2009135118A2 (en) 2008-05-02 2009-11-05 Virginia Commonwealth University Lyme disease vaccine
EP2569008B1 (en) 2010-05-14 2019-12-25 Baxalta Incorporated Ospa chimeras and use thereof in vaccines
CN104640563A (zh) * 2012-07-27 2015-05-20 巴克斯特国际公司 包含嵌合的ospa分子的组合物及其使用方法

Similar Documents

Publication Publication Date Title
JP2013529078A5 (cg-RX-API-DMAC7.html)
JP2013529077A5 (cg-RX-API-DMAC7.html)
RU2012153752A (ru) Химерные гены ospa, белки и способы их применения
RU2017144098A (ru) Гетеродимеризованный полипептид
JP6505110B2 (ja) ＯｓｐＡの突然変異体断片、並びにそれに関する方法および使用
JP2015522270A5 (cg-RX-API-DMAC7.html)
CN101891806B (zh) 抗黄病毒包膜e蛋白的单克隆抗体及其应用
US11352416B2 (en) Mosaic chimeric viral vaccine particle
CN109734800B (zh) 一种裂谷热病毒人源单克隆抗体及其应用
US12377138B2 (en) Treatment and prevention of malaria
CA3232870A1 (en) Coronavirus vaccines and methods of use
CN102690789B (zh) 分泌破伤风外毒素单克隆抗体的杂交瘤细胞株及由其制备的单克隆抗体、Fab抗体与应用
CA3185087A1 (en) Immunostimulatory adjuvants
JP2015529677A5 (cg-RX-API-DMAC7.html)
JP2023540778A (ja) Ａｃｅ２結合力が減少したコロナウイルス由来の受容体結合ドメイン変異体及びこれを含むワクチン組成物
CN112390884B (zh) Semaphorin7A单克隆抗体及其在制备用于治疗炎症疾病药物方面的应用
WO2022254433A1 (en) Reconstitution and uses of flavivirus epitopes
CN102219858A (zh) 微小隐孢子虫ctl多表位基因和融合蛋白及其应用
WO2016207408A1 (en) Novel vaccines in prevention and treatment of malaria
CN105254719B (zh) 金黄色葡萄球菌trap蛋白的cd4+t细胞表位鉴定及其重组表位疫苗
WO2023279803A1 (zh) Rbv的蛋白结合分子及其用途
CN107034198A (zh) 一种嵌合诺如病毒p颗粒及其制备和应用
CN110483624A (zh) 伽氏疏螺旋体OspA蛋白C端肽段及其应用
TW202306966A (zh) 人類α突觸核蛋白之抗原決定位肽及包含該肽之醫藥組合物
최훈철 Development of recombinant vaccine against Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV)